Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from a Phase I trial (NCT05240898) of KSQ-4279 (RO7623066), a potent USP1 inhibitor, alone and in combination with olaparib or carboplatin in patients with HRR-mutated tumors. Treatment-emergent adverse events and preliminary efficacy results, including disease control rates and response duration, were examined, and trial supports the potential of KSQ-4279 as a first-in-class treatment, highlighting its safety and mechanism of action in DNA damage response pathways. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
